Pargyline
产品说明书
 |
同义名 : | 优降宁 |
| CAS号 : | 555-57-7 | |
| 货号 : | A735949 | |
| 分子式 : | C11H13N | |
| 纯度 : | 98% | |
| 分子量 : | 159.23 | |
| MDL号 : | MFCD00008576 | |
| 存储条件： |
Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(659.43 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline (0.5-2 mM; 24-120 hours) treatment inhibits the proliferation of LNCaP-LN3 cells in a time- and dose-dependent manner. Pargyline (0.5-2 mM; 24-48 hours) treatment decreases S phase and increases the G1 phase in the cells in a dose-dependent manner. Pargyline (0.5 mM; 24 hours) treatment increases the apoptotic cells. Pargyline (2 mM; 48 hours treatment induces an increase of cytochrome c and a decrease of caspase-3 in the cells, but does not lead to a change of BCL-2 expression[2]. Pargyline (10 mg/kg; iv) treatment induces a moderate (about 20 mm Hg) but persistent (48 h) decrease of systolic blood pressure in unanesthetized adult spontaneously hypertensive rats (SHR) but not in normotensive rats. A low dose of Pargyline (200 μg; icv) injected directly into the brain lowered arterial pressure. The hypotensive action of Pargylline in SHR appears to be the consequence of Norepinephrine accumulating at an inhibitory α-adrenoceptor in brain[3]. Oral pargyline treatment protected transplanted beta cells in diabetic mice, thus leading to disease reversal. Furthermore, pargyline prevented or delayed diabetes onset in several mouse models for T1D(Type 1 diabetes)[4]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
6.28mL 1.26mL 0.63mL |
31.40mL 6.28mL 3.14mL |
62.80mL 12.56mL 6.28mL |
| 参考文献 |
|---|